Is pazopanib (800 mg orally once daily) indicated for unresectable or metastatic synovial sarcoma after progression on first‑line anthracycline‑based chemotherapy?

Pazopanib for Synovial Sarcoma: Indicated After Anthracycline Failure

Yes, pazopanib 800 mg orally once daily is indicated for unresectable or metastatic synovial sarcoma after progression on anthracycline-based chemotherapy, with FDA approval for metastatic non-lipogenic soft tissue sarcomas in this setting. 1

FDA-Approved Indication

Pazopanib received FDA approval specifically for soft tissue sarcomas (excluding gastrointestinal stromal tumors and adipocytic sarcomas) in patients who have received prior chemotherapy 1. The pivotal trial (VEG110727) included synovial sarcoma as a distinct cohort, demonstrating:

• Median PFS: 4.1 months vs 0.9 months for placebo (HR 0.43,95% CI: 0.19-0.98) 1
• Overall trial population PFS: 4.6 months vs 1.6 months (p<0.001) 1
• Clinical benefit rate of 4% in the overall population 1

Guideline Recommendations

NCCN Guidelines (2022)

The NCCN explicitly includes pazopanib as a treatment option for advanced/metastatic nonlipogenic soft tissue sarcomas (which includes synovial sarcoma) in two settings 2:

• First-line therapy: For patients ineligible for intravenous systemic therapy or not candidates for anthracycline-based regimens 2
• Subsequent-line palliative therapy: After progression on anthracycline-based chemotherapy 2

ESMO-EURACAN Guidelines (2021)

Pazopanib is recommended as an option in non-adipogenic soft tissue sarcomas in second and further lines of treatment with Level I, B evidence and ESMO-MCBS score of 3 2.

SELNET Guidelines (2022)

Pazopanib is listed as an option except for adipogenic soft tissue sarcomas after progression to standard chemotherapy, with evidence level II, E 2.

Clinical Evidence Specific to Synovial Sarcoma

The EORTC 62043 phase II study demonstrated specific activity in synovial sarcoma 3:

• Progression-free rate at 12 weeks: 49% (18 of 37 patients) 3
• This met the pre-specified efficacy threshold and led to continuation of enrollment 3
• Prolonged progression-free and overall survival compared to historical controls treated with second-line chemotherapy 3

Treatment Algorithm for Synovial Sarcoma

First-line: Anthracycline-based chemotherapy (doxorubicin ± ifosfamide) remains standard 2

Second-line options after anthracycline failure (in order of preference based on evidence):

1. Pazopanib 800 mg daily - FDA-approved, Level I evidence 1, 2
2. Trabectedin - Particularly effective in translocation-related sarcomas including synovial sarcoma 2
3. High-dose ifosfamide (12-14 g/m²/cycle) - If not adequately dosed in first-line 2
4. Regorafenib - Demonstrated PFS benefit in synovial sarcoma cohort of REGOSARC trial 2

Critical Caveats

Exclusion of liposarcomas: Pazopanib specifically excludes adipocytic sarcomas due to lack of efficacy in this subtype 2, 1. Synovial sarcoma is non-adipocytic and therefore appropriate for pazopanib treatment.

Dose modifications: Start at 800 mg daily; dose reductions to 400 mg may be necessary for toxicity management 4. Real-world data shows dose reductions were required in 56% of patients 4.

Common toxicities to monitor 1, 3:

• Hypertension (grade 3-4 in 7.7%)
• Liver enzyme elevations (hyperbilirubinemia grade 3-4 in 6.3%)
• Fatigue (grade 3-4 in 7.7%)
• Diarrhea, nausea, hypopigmentation (mostly grade 1-2)

Pneumothorax risk: Case reports document spontaneous pneumothorax in synovial sarcoma patients on pazopanib, though causality remains unclear as lung metastases themselves can cause pneumothorax 5.

Alternative Consideration: NTRK Fusion Testing

Before initiating pazopanib, consider NTRK fusion testing, as synovial sarcomas can harbor NTRK fusions 2. If NTRK fusion-positive, larotrectinib or entrectinib are recommended as first-line treatment options with superior efficacy 2.

Real-World Performance

Real-world data shows pazopanib is more effective in earlier lines of treatment 4. In heavily pre-treated populations (median third-line use), median PFS was 3 months and OS was 7 months, shorter than the pivotal trial but still demonstrating clinical benefit 4.